Faruqi & Faruqi Probes Investor Claims Against Rezolute Inc

Reuters
Yesterday
Faruqi & Faruqi Probes Investor Claims Against Rezolute Inc

Faruqi & Faruqi said it is investigating potential securities claims on behalf of investors in Rezolute Inc. following a sharp selloff in the company’s shares after disappointing topline results from its Phase 3 sunRIZE trial of ersodetug for congenital hyperinsulinism. The firm alleges investors who suffered significant losses in Rezolute stock or options may have legal rights and is seeking to speak with affected shareholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602190951PRIMZONEFULLFEED9657199) on February 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10